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Summary
Background Hypertension is considered the most important risk factor for cardiovascular diseases, but its control is 
poor worldwide. We aimed to assess the availability and affordability of blood pressure-lowering medicines, and the 
association with use of these medicines and blood pressure control in countries at varying levels of economic 
development.
Methods We analysed the availability, costs, and affordability of blood pressure-lowering medicines with data recorded 
from 626 communities in 20 countries participating in the Prospective Urban Rural Epidemiological (PURE) study. 
Medicines were considered available if they were present in the local pharmacy when surveyed, and affordable if their 
combined cost was less than 20% of the households’ capacity to pay. We related information about availability and 
affordability to use of these medicines and blood pressure control with multilevel mixed-effects logistic regression 
models, and compared results for high-income, upper-middle-income, lower-middle-income, and low-income 
countries. Data for India are presented separately because it has a large generic pharmaceutical industry and a higher 
availability of medicines than other countries at the same economic level.
Findings The availability of two or more classes of blood pressure-lowering drugs was lower in low-income and 
middle-income countries (except for India) than in high-income countries. The proportion of communities with 
four drug classes available was 94% in high-income countries (108 of 115 communities), 76% in India (68 of 90), 
71% in upper-middle-income countries (90 of 126), 47% in lower-middle-income countries (107 of 227), and 13% 
in low-income countries (nine of 68). The proportion of households unable to afford two blood pressure-lowering 
medicines was 31% in low-income countries (1069 of 3479 households), 9% in middle-income countries (5602 of 
65 471), and less than 1% in high-income countries (44 of 10 880). Participants with known hypertension in 
communities that had all four drug classes available were more likely to use at least one blood pressure-lowering 
medicine (adjusted odds ratio [OR] 2·23, 95% CI 1·59–3·12); p<0·0001), combination therapy (1·53, 1·13–2·07; 
p=0·054), and have their blood pressure controlled (2·06, 1·69–2·50; p<0·0001) than were those in communities 
where blood pressure-lowering medicines were not available. Participants with known hypertension from 
households able to afford four blood pressure-lowering drug classes were more likely to use at least one blood 
pressure-lowering medicine (adjusted OR 1·42, 95% CI 1·25–1·62; p<0·0001), combination therapy (1·26, 
1·08–1·47; p=0·0038), and have their blood pressure controlled (1·13, 1·00–1·28; p=0·0562) than were those 
unable to afford the medicines.
Interpretation A large proportion of communities in low-income and middle-income countries do not have access to 
more than one blood pressure-lowering medicine and, when available, they are often not affordable. These factors are 
associated with poor blood pressure control. Ensuring access to affordable blood pressure-lowering medicines is 
essential for control of hypertension in low-income and middle-income countries.
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Introduction
Hypertension affects 1 billion people worldwide and is a 
major risk factor for cardiovascular disease (CVD).1 
Although blood pressure-lowering medicines reduce 
CVD events, renal failure, and mortality,2 their use is 
suboptimal and blood pressure control is poor.3
Most individuals with hypertension require at least two 
blood pressure-lowering medicines to adequately control 
their blood pressure.4 Diuretics, angiotensin-converting 
enzyme (ACE) inhibitors, calcium-channel blockers, and 
β blockers all reduce CVD5 and are the most commonly 
used blood pressure-lowering medicines. However, use of 
combination therapy is low, particularly in low-income 
and middle-income countries.3 Moreover, although blood 
pressure-lowering medicines are listed in the WHO 
Model list of Essential Medicines,6 little is known about 
their availability and affordability and the relation to 
hypertension control. About one in four people with 
hypertension also have diabetes,7,8 and trials indicate that 
statins double the benefit of blood pressure-lowering drug 
therapy by further reducing CVD events.9,10 Therefore, 
optimal management would include a combination of at 
least two blood pressure-lowering medicines, a statin, and 
added antidiabetic drug (when needed).
Here we describe the availability and affordability of 
the four common classes of blood pressure-lowering 
medicines, statins, and metformin in 20 countries at 
varying levels of economic development, and examine 
the association with use of these medicines and blood 
pressure control.
Methods
Study design and participants
The Prospective Urban Rural Epidemiological (PURE) 
study recruited 181 162 individuals aged 35–70 years. We 
analysed the first phase of the study, which included 
158 247 individuals from 110 677 households living in 
626 communities in 20 countries, for whom a full set of 
data required for this analysis are available.11–14 Participant 
enrolment began in January, 2003; most communities 
were recruited between January, 2005, and December, 2009 
and the process is continuing as new countries join. The 
countries and communities were selected purposively, with 
the aim of obtaining a socioeconomically and culturally 
diverse study sample. Within participating communities, 
the goal was to enrol a representative sample of households 
while also ensuring feasibility of long-term follow-up.11 
Although not designed to be nationally representative, we 
have previously shown that the characteristics and death 
rates of the enrolled participants were similar to their 
national populations.12 A comprehensive description of 
study design, sampling, recruitment practices, and 
Research in context
Evidence before this study
We searched PubMed on March 1, 2017, with no language or 
date restrictions, for articles on the availability and affordability 
of blood pressure-lowering medicines in countries at various 
stages of economic development. Our search terms included 
“availability”, “affordability”, “blood pressure lowering drugs or 
medicines”, and “antihypertensive”. We excluded studies that 
did not include a measure of affordability.
We identified four studies that assessed the availability and 
affordability of different medicines, including blood 
pressure-lowering medicines. Only two studies provided a 
description of the availability of blood pressure-lowering 
medicines; one for six low-income and middle-income countries 
and the other in 36 countries of high, middle, and low income. 
Both studies estimated affordability using the number of days’ 
wages needed to pay the lowest paid, unskilled government 
worker to purchase a 1 month supply of the medicines. This 
approach to estimation of affordability does not allow for 
interhousehold comparisons. Neither study assessed the 
association between availability and affordability and use of 
blood pressure-lowering medicines or blood pressure control.
Added value of this study
Our study describes the availability and affordability of commonly 
used blood pressure-lowering medicines, as well as combination 
therapy using multiple therapies (eg, antidiabetic drug and a 
statin), in countries of high, upper-middle, lower-middle, and low 
income. Furthermore, to our knowledge, our study is the first to 
examine the association between availability and affordability of 
blood pressure-lowering medicines and use of these medicines 
and blood pressure control.
Our findings show that a large proportion of communities in 
low-income and middle-income countries do not have access 
to more than one blood pressure-lowering medicine and, when 
available, they are often not affordable. Our results indicate that 
multiple blood pressure-lowering drug classes need to be 
available and affordable to improve hypertension control.
Implications of all the available evidence
Improvement of the availability and affordability of blood 
pressure-lowering medicines is essential to improve control of 
hypertension, particularly in low-income and middle-income 
countries, where 80% of the cardiovascular disease (CVD) 
burden exists. Our results are therefore directly relevant to 
public policies targeted at reducing the global burden of CVD, 
particularly the goal of a 25% reduction in premature CVD 
deaths by 2025, and the even more ambitious targets in the 
Sustainable Development Goals.
However, improvement of hypertension control at the 
population level will also require strategies beyond improvement 
of access to low-cost blood pressure-lowering medicines. Further 
research is warranted into contextual and cultural barriers, factors 
associated with the health-care system, and personal preferences.
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participant characteristics has been previously published 
and is available in the appendix.11–14
We categorised countries into four groups on the basis 
of the World Bank classification at the time the PURE 
study started (2006). The countries include four high-
income countries (Sweden, United Arab Emirates, 
Canada, and Saudi Arabia), seven upper-middle-income 
countries (Poland, Turkey, Chile, Malaysia, South Africa, 
Argentina, and Brazil), four lower-middle-income 
countries (Colombia, Iran, China, and the occupied 
Palestinian territory), and five low-income countries 
(Pakistan, Bangladesh, Zimbabwe, Tanzania, and India). 
Data for India are presented separately because it has a 
large generic pharmaceutical industry and previous work 
has shown that availability of medicines is higher in India 
than in other countries at the same economic level.15
Ethics committees at each participating centre 
approved the protocol11,12,14 and all participants provided 
written informed consent.11
Data collection
Availability and prices of blood pressure-lowering 
medicines were collected by research staff from one 
pharmacy in each community with the Environmental 
Profile of a Community’s Health (EPOCH) instrument—a 
reliable and validated tool developed for measuring 
aspects of the environment that influence cardiovascular 
risk factors.15–17 Briefly, communities with at least 30 PURE 
participants were included in EPOCH, which has two 
parts: direct observation of the physical and commercial 
environment and a survey of perceptions of the 
environment by those living in it.
In the direct observation component, the pharmacy 
closest to the prespecified central location was visited by 
research staff to obtain information about the availability 
of medicines and their prices between Jan 1, 2009, and 
April 19, 2016. We collected information about the 
availability and price of three widely used ACE inhibitors 
(captopril, enalapril, and ramipril), two β blockers 
(esatenolol [atenolol] and meto prolol), one calcium-
channel blocker (amlodipine), and one diuretic (hydro-
chloro thiazide). Many patients with hypertension also 
have cardiovascular disease, diabetes, or other indications 
for statins.18 We therefore present the availability and price 
of two widely used statins (atorvastatin and simvastatin) 
and metformin (commonly used for diabetes).
In the community survey component, trained 
interviewers collected data from all households and 
individuals participating in the PURE study using 
standardised questionnaires. Information about monthly 
household income and food expenditure was obtained 
from a knowledgeable member in each household. 
Names of all medicines taken at least once per week in 
the past month by all PURE participants were recorded 
by direct inspection of medicines or prescriptions. 
Medicines were then coded in the central project office 
and categorised by drug classes.
Trained research assistants measured sitting blood 
pressure twice after a 5 min rest period for all PURE 
participants by use of a standardised procedure with 
a digital blood pressure measuring device (Omron 
HEM-757; Omron, Tokyo, Japan). Individuals were 
deemed hypertensive if they reported having a 
hypertension diagnosis and receiving blood pressure-
lowering treatments, or if the average of two systolic 
blood pressures was at least 140 mm Hg or the average of 
two diastolic blood pressures was at least 90 mm Hg. 
Individuals with known hypertension were the 
proportion of patients aware of their hypertension 
diagnosis. Of these individuals, those whose systolic and 
diastolic blood pressures were less than 140/90 mm Hg 
were considered to have controlled hypertension.
Definition of availability and affordability
Blood pressure-lowering medicines were considered 
available if they were physically present in the local 
pharmacy surveyed on the day of data collection.15 Total 
monthly costs of the medicines were estimated with 
standard doses and recommended frequencies 
(appendix). The medicines were deemed affordable if 
the total monthly cost of the lowest cost medicines was 
less than 20% of households’ monthly capacity to pay, 
consistent with the literature on catastrophic health 
expenditure19 and our previous work.15 We estimated 
capacity to pay by subtracting basic subsistence 
needs, which we defined as household expenditure on 
food, from monthly household income. In a sensitivity 
analysis, we also subtracted household expenditure on 
housing (defined as expenditures on rent, mortgage, 
and utilities), transportation (defined as expenditures 
on public transit fares and personal vehicle), and food 
from monthly household income in a subset of PURE 
participants for whom such data were currently 
available.
We present equivalised capacity to pay, for which 
capacity-to-pay estimates were divided by the square root 
of the household size to allow for interhousehold 
comparisons. Household incomes, expenditures, and 
medicine costs were converted from their local currencies 
into 2010 US$, (after adjustment for inflation20), by use of 
purchasing power parities from the World Bank.21 We also 
did sensitivity analyses for thresholds ranging from 10% 
to 40% of households’ capacity to pay (appendix). In our 
2016 study,15 we showed that household capacity to pay is 
strongly correlated with a household wealth index as well 
as capacity-to-pay values from the WHO World Health 
Survey, which confirms the robustness of our measure of 
capacity to pay (appendix). As discussed in that study, we 
assumed that participants purchased their medicines 
from pharmacies rather than non-pharmacy retailers.15 
Furthermore, we assumed that households pay the full 
cost of the medicines—ie, the costs of the medicines are 
not partly or fully subsidised by governments or other 
third parties (eg, health insurance).
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Statistical analysis
We estimated the association between availability and 
affordability and use of blood pressure-lowering 
medicines and blood pressure control in separate models 
for participants with known hypertension. Our analysis 
used multilevel, mixed-effects logistic regression models, 
accounting for clustering at the community level 
(appendix). All statistical models were adjusted for the 
potential confounders of age, sex, education level, years 
since hypertension diagnosis, and urban versus rural 
geographical location. For the affordability analysis, we 
excluded households that did not report information 
about income or food expenditure, because the absence 
of this information precluded us from estimating 
capacity to pay. We report adjusted and unadjusted 
associations as odds ratios (ORs) with 95% CIs. All 
statistical analyses were done with Stata (version 14).
Role of the funding source
The funders and sponsors of the study had no role in 
study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding 
author had full access to all the data in the study and had 
final responsibility for the decision to submit for 
publication.
Results
564 (90%) of 626 communities had at least one blood 
pressure-lowering medicine available in the local 
pharmacy surveyed (figure 1). The 62 (10%) communities 
with no available blood pressure-lowering medicines were 
mainly located in low-income and lower-middle-income 
countries (figure 1). Most communities in high-income 
countries (108 [94%] of 115) and India (68 [76%] of 90) had 
all four drug classes available (figure 1). Availability of all 
four drug classes was lowest in low-income countries 
(nine [13%] of 68), excluding India (figure 1). We also 
noted urban and rural differences in the availability of 
blood pressure-lowering drugs; these differences were 
most marked in lower-middle-income and low-income 
countries. For example, 64 (57%) of 112 urban communities 
in lower-middle-income countries had at least four drug 
classes compared with 43 (37%) of 115 rural communities 
(appendix).
The most common drug class varied across regions; 
β blockers and calcium-channel blockers were the 
most commonly available drug classes in countries of 
upper-middle income (110 [87%] and 104 [83%] of 
126 communities, respectively) and low income (57 [84%] 
and 47 [69%] of 68 communities, respectively), whereas 
ACE inhibitors and β blockers were the most commonly 
available drugs in countries of lower-middle income 
(182 [80%] and 156 [69%] of 227 communities, respectively; 
appendix). In each group of countries, diuretics were the 
least expensive drug class, followed by β blockers (data 
not shown).
We excluded 13 589 households from the affordability 
analysis that did not report information about income or 
food expenditure. Individuals in households that reported 
household income and food expenditure were similar to 
those in households that did not (appendix). Moreover, 
imputing the mean value within each community for 
individuals with missing information about household 
income and food expenditure did not alter the associations. 
Median monthly capacity to pay was highest in high-
income countries and lowest in low-income countries 
(table 1). Household capacity to pay was lower in rural 
communities across all country groups, with substantial 
differences in upper-middle-income (urban US$416 vs rural 
$183) and low-income countries ($78 vs $32), including 
India ($167 vs $26; appendix).
The monthly costs of the lowest, lowest two, and lowest 
three cost blood pressure-lowering medicines were 
highest in absolute terms in high-income countries but, 
in view of the much higher incomes in high-income 
countries, this constituted a lower proportion of 
household capacity to pay than in low-income countries 
(<1% in high-income countries compared with 1–11% in 
low-income countries for one to three blood pressure-
lowering medicines; table 1). The monthly costs of the 
lowest cost drugs in upper-middle-income countries 
were similar to high-income countries; however, they 
accounted for a larger fraction of household capacity to 
pay in upper-middle-income countries (table 1). This 
observation is largely driven by differences in household 
capacity to pay between high-income and upper-middle-
income countries; median capacity to pay in high-income 
communities was roughly nine times that in upper-
middle-income countries (table 1). The difference in 
capacity to pay between high-income and upper-middle-
income communities was further exacerbated once we 
took into account household expenditure on housing and 
transportation in the sensitivity analysis (a roughly 
Figure 1: Availability of BP-lowering medicines in 626 PURE communities 
Error bars represent 95% CIs. BP=blood pressure. HIC=high-income countries. UMIC=upper-middle-income countries. 
LMIC=lower-middle-income countries. LIC=low-income countries. *Excluding India.
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12 times difference). Communities in lower-middle-
income countries had some of the lowest monthly costs 
for blood pressure-lowering medicines (table 1). However, 
when the monthly cost of metformin or the lowest cost 
statin was added to the cost of the two lowest cost drugs, 
the median monthly costs increased considerably in 
lower-middle-income and low-income countries (table 1).
Few households (44 [<1%] of 10 880) in high-income 
countries were unable to afford the two lowest cost blood 
pressure-lowering medicines (figure 2), even after taking 
into account the costs of housing and transportation. 
The proportion of households unable to afford the 
two lowest cost drugs was highest in low-income 
countries (1069 [31%] of 3479), including India 
(6139 [36%] of 16 955), which had the highest proportion 
of households unable to afford hypertension medicines 
(figure 2). Adding the cost of metformin or the lowest 
cost statin to the monthly cost of the two lowest cost blood 
pressure-lowering medicines increased the proportion of 
households unable to afford the medicines, but the 
increase was most marked in lower-middle-income and 
low-income countries (figure 2). For example, in low-
income countries, 1069 (31%) of 3479 households were 
unable to afford the monthly cost of the two lowest cost 
blood pressure-lowering medicines; adding metformin 
increased the proportion to 39% (n=1366), adding the 
lowest cost statin increased the proportion to 
75% (n=2277), and including both metformin and the 
lowest cost statin increased the proportion to 
80% (n=2441). By contrast, almost all households in high-
income countries were able to afford the cost of the two 
lowest cost drugs and metformin (10 809 [99%] of 10 880), 
the two lowest cost drugs and the lowest cost statin 
(10 638 [98%]), or all drugs (10 579 [97%]; figure 2).
In our sensitivity analysis, in which we revised our 
estimates of household capacity to pay by excluding 
monthly household expenditure on housing, trans-
portation, and food, from monthly household income in 
a subset of participants (n=23 888), the proportion of 
households unable to afford the lowest cost blood 
pressure-lowering medicines increased in all countries, 
categorised according to economic development; 
however, the pattern was similar to that in the main 
analysis (appendix).
Our subsequent analysis was restricted to the subset of 
participants with known hypertension (n=33 045; table 2), 
of whom 19 481 (59%) used at least one blood pressure-
lowering medicine, 8697 (26%) used ACE inhibitors or 
angiotensin II receptor blockers, 6221 (19%) used diuretics, 
5028 (15%) used β blockers, and 5146 (16%) used calcium-
channel blockers. Use of combination therapy was 
relatively low, with only 7879 (24%) participants taking 
more than one blood pressure-lowering medicine (6160 
[19%] of 33 045 were taking two drugs, 1489 [5%] were 
taking three drugs, and 212 [<1%] were taking four drugs). 
Table 2 shows the baseline characteristics of the population 
with hypertension.
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Participants with known hypertension living in 
communities that had all four blood pressure-lowering 
drug classes available were more likely to use at least one 
blood pressure-lowering medicine, combination therapy, 
or have their blood pressure controlled, than were those 
living in a community where blood pressure-lowering 
medicines were not available (figure 3). Similarly, 
participants with known hypertension who were able to 
afford up to four blood pressure-lowering medicines were 
more likely to use at least one blood pressure-lowering 
medicine, combination therapy, or have their blood 
pressure controlled than were the group not able to afford 
these medicines (figure 3).
Discussion
Blood pressure-lowering medicines are listed as WHO 
essential medicines, but their access remains a global 
concern. Although at least one blood pressure-lowering 
medicine was available in 90% of the pharmacies 
surveyed, the availability of two or more classes of drug 
therapy was lower in low-income and lower-middle-
income countries than in high-income countries (and 
India). Our findings with respect to affordability parallel 
the patterns observed for availability, with one important 
exception: even though blood pressure-lowering 
medicines were widely available in India, they were 
potentially unaffordable to many households because of 
low capacity to pay and higher medicine prices than in 
other low-income countries.
Among participants aware of their hypertension 
diagnosis, we recorded strong positive associations 
between availability and affordability of blood pressure-
lowering medicines and use of these medicines (including 
combination therapy) and blood pressure control. Our 
results indicate that multiple blood pressure-lowering 
drug classes need to be available and affordable to improve 
hypertension control. This finding could reflect the needs 
of different patients or the preferences of different 
physicians for prescribing specific blood pressure-
lowering drugs. Physicians might prefer to prescribe 
different classes of blood pressure-lowering drugs to 
patients under the assumption that patients differ in their 
High-income countries Upper-middle-income 
countries
Lower-middle-income 
countries
Low-income countries
Men Women Men Women Men Women Men Women
N 1809 1828 4297 7567 4691 7143 2175 3535
Age (years) 58 (8·3) 57 (8·1) 57 (8·8) 56 (8·9) 56 (9·3) 56 (8·6) 55 (9·7) 53 (9·9)
Education level
Low* 277 (15%) 448 (25%) 2273 (53%) 4801 (63%) 1558 (33%) 3864 (54%) 481 (22%) 1839 (52%)
Secondary 537 (30%) 591 (32%) 1252 (29%) 1983 (26%) 2084 (44%) 2525 (35%) 1008 (46%) 1339 (38%)
University 991 (55%) 789 (43%) 767 (18%) 776 (10%) 1040 (22%) 741 (10%) 681 (31%) 342 (10%)
Time since hypertension diagnosis (years)
1–5 665 (37%) 602 (33%) 1726 (40%) 2920 (39%) 1784 (38%) 2690 (38%) 935 (43%) 1470 (42%)
>5 905 (50%) 956 (52%) 1937 (45%) 3689 (49%) 2191 (47%) 3451 (48%) 764 (35%) 1307 (37%)
Living in a rural community 514 (28%) 539 (29%) 1922 (45%) 3397 (45%) 2064 (44%) 3040 (43%) 718 (33%) 1444 (41%)
Blood pressure controlled† 633 (35%) 697 (38%) 829 (19%) 2017 (27%) 886 (19%) 1562 (22%) 548 (25%) 766 (22%)
Diagnosis of cardiovascular 
disease‡
341 (19%) 182 (10%) 568 (13%) 657 (9%) 1031 (22%) 1196 (17%) 259 (12%) 258 (7%)
Diagnosis of diabetes§ 512 (28%) 448 (25%) 1170 (27%) 1927 (25%) 974 (21%) 1384 (19%) 736 (34%) 986 (28%)
Data are mean (SD) or n (%), unless otherwise stated. *Defined as no education, primary education only, or unknown educational level. †Defined as systolic and diastolic 
blood pressures of less than 140/90 mm Hg. ‡ Defined as an individual with previous stroke or coronary artery disease (eg, myocardial infarction, coronary artery bypass graft 
surgery, percutaneous coronary angioplasty, or angina). §Defined as self-reported or fasting blood glucose concentrations of 7 mmol/L or more.
Table 2: Baseline characteristics of participants aware of their hypertension diagnosis (n=33 045) 
Figure 2: Proportion of households that could not afford blood pressure-lowering medicines and 
combination therapy (n=98 785)
With a 20% capacity-to-pay threshold. Error bars represent 95% CIs. HIC=high-income countries. 
UMIC=upper-middle-income countries. LMIC=lower-middle-income countries. LIC=low-income countries. 
*Excluding India and Zimbabwe. †Tanzania excluded because statins were unavailable.
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response and tolerance to different medicines. Previous 
studies have shown that hypertension treatment practices 
(eg, blood pressure threshold for initiation of drug therapy, 
or use of specific drugs) vary by patient characteristics, 
their risk, and by region, and these factors can change 
over time.22 Our estimates for affordability and use of 
blood pressure-lowering medicines and blood pressure 
control are consistent with findings from studies showing 
that adherence to medicines declines as out-of-
pocket expenditure increases, whereas improvements in 
insurance coverage for medicine costs and low out-of-
pocket expenditure improves adherence.23,24 These results 
show the importance of development of policies that seek 
to make multiple drug classes available and affordable, 
particularly in low-income and middle-income countries.
We estimate that the median monthly retail cost of the 
two lowest cost blood pressure-lowering medicines is 
roughly $4·95. This cost varies from $0·33 in lower-
middle-income countries (where the medicines are 
subsidised by governments—eg, in the occupied 
Palestinian territory and Iran25) to $16·68 in high-income 
countries. Previous studies have reported costs for a 
multidrug regimen targeting hypertension and cardio-
vascular disease,26 and costs for delivery of a hypertension 
management programme that includes at least one blood 
pressure-lowering medicine.27 However, we obtained our 
medicine prices directly from the community retail 
pharmacies in which the PURE participants lived, and 
therefore represent prices members of that community 
would actually face, which include mark-ups along the 
supply chain. By contrast, medicine prices used in the 
costing exercises done for the multidrug regimen26 and 
hypertension management programme27 use median 
procurement prices obtained from the International 
Reference Price Index created by Management Sciences 
for Health for a select number of developing countries. 
Previous studies have shown marked differences between 
prices charged to patients and procurement prices.28 
Furthermore, although organisations such as Health 
Action International have done extensive studies into the 
availability and pricing of medicines in many countries,28–30 
our study is, to our knowledge, the first attempt to link 
such data to use of blood pressure-lowering drugs in 
countries of different economic levels.
Improvement of hypertension control at a population 
level will require strategies beyond improvement of access 
to low-cost blood pressure-lowering medicines.31 For 
example, although costs attributed to health-care access 
are important barriers in low-income and lower-middle-
income countries, additional barriers imposed by 
providers, the broader health systems in which they work 
(eg, access to a qualified health provider) and patient 
characteristics (eg, health literacy) are important factors for 
achievement of blood pressure control.31 In high-income 
countries, the effect of availability and affordability was 
minimal, indicating that other factors are important for 
blood pressure control in these countries. Further research 
into contextual and cultural barriers, factors associated 
with the health-care system, and personal preferences 
have been done, with additional studies underway in 
PURE.32,33 These studies will help develop a comprehensive 
approach to improve hypertension control globally from 
the current levels whereby only 13% of individuals with 
hypertension have controlled blood pressure. However, on 
the basis of our data, improvement of access to affordable 
blood pressure-lowering medicines in low-income and 
Figure 3: Associations between availability and affordability and use of at least one blood pressure-lowering medicine, combination therapy, and blood 
pressure control in participants with known hypertension (n=33 045)
Adjusted for age, sex, education, years since hypertension diagnosis, urban versus rural location; clustered at the community level. OR=odds ratio. *Affordability 
analysis restricted to participants living in communities where at least one blood pressure-lowering medicine was available. In calculating affordability, we used the 
cost of the lowest cost medicine.
Use of at least one antihypertensive
Four available
Three available
Two available
None or one available
Use of combination therapy
Four available
Three available
Two available
None or one available
Effect on blood pressure control
Four available
Three available
Two available
None or one available
2·23 (1·59–3·12)
0·74 (0·47–1·15)
0·93 (0·56–1·52)
1·00 (1·00–1·00)
1·53 (1·13–2·07)
0·54 (0·36–0·81)
0·82 (0·52–1·30)
1·00 (1·00–1·00)
2·06 (1·69–2·50)
1·32 (1·02–1·71)
0·80 (0·59–1·08)
1·00 (1·00–1·00)
Use of at least one antihypertensive
Four affordable
Three affordable
Two affordable
None or one affordable
Use of combination therapy
Four affordable
Three affordable
Two affordable
None or one affordable
Effect on blood pressure control
Four affordable
Three affordable
Two affordable
None or one affordable
1·42 (1·25–1·62)
1·26 (1·10–1·46)
1·03 (0·88–1·20)
1·00 (1·00–1·00)
1·26 (1·08–1·47)
1·23 (1·03–1·46)
0·97 (0·80–1·18)
1·00 (1·00–1·00)
1·13 (1·00–1·28)
0·98 (0·85–1·14)
0·99 (0·84–1·16)
1·00 (1·00–1·00)
0·5 1·0 1·5 2·0 3·5
OR
0·5 1·0 1·5 2·0 3·5
OR
OR (95% CI) OR (95% CI)Availability Affordability*
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lower-middle-income countries is likely to substantially 
improve rates of hypertension control in these countries.
Our study has some limitations. In the estimation of 
affordability, we assumed that households paid the full 
retail price; therefore, our findings do not take into 
account the role of insurance or any other form of 
reimbursement individuals or households might receive. 
However, previous studies have indicated that most 
pharmaceutical expenditure in low-income and lower-
middle-income countries occurs in the private sector, 
often in the form of out-of-pocket expenditure.34 Some 
patients might prioritise other expenses over the treatment 
of their hypertension; our measure of affordability does 
not take into account participant prioritisation or 
preferences. If medicines are more readily available from 
non-pharmacy vendors or in pharmacies not surveyed in 
our study, our estimates of availability are underestimates 
of true availability.
The methods we used to define hypertension and blood 
pressure control are standard in large epidemiological 
studies. Although multiple blood pressure measurements 
on three to five occasions would provide greater precision, 
this approach is not feasible in large multicountry studies 
involving more than 100 000 participants, and is rarely 
done in routine clinical practice in most settings, 
especially in lower-middle-income countries.
Of the new drug classes for blood pressure lowering, 
angiotensin II receptor blockers are used with some 
frequency, especially when ACE inhibitors are not 
tolerated. However, drugs in this class are more expensive 
than ACE inhibitors, as such, our estimates for 
affordability are unlikely to change. Furthermore, 
because we used cross-sectional observational data, we 
cannot show that the associations between availability 
and affordability, and medicine use and blood pressure 
control, are causal.
Our results are directly relevant to public policies that are 
targeted at reducing the global burden of CVD by 
improving access to essential medicines, particularly the 
stated goals of a 25% reduction in premature CVD deaths 
by 2025, and the even more ambitious targets in the 
Sustainable Development Goals.35 Until key lifesaving 
medicines are available and affordable to most populations, 
hypertension control is likely to be suboptimal, especially 
in low-income and lower-middle-income countries. 
Similar conclusions can be drawn from Khatib and 
colleagues’ 2016 report15 with regards to improving use of 
proven medicines for secondary prevention. In the context 
of hypertension control, many patients also have diabetes, 
CVD, or other indications for statins. Such patients are at 
high risk and will benefit from combination therapy, which 
could include two blood pressure-lowering drugs, a 
statin, or metformin.10,36 However, these drug therapy 
combinations are unaffordable for most people in low-
income and lower-middle-income countries. For example, 
a combination therapy that includes the two lowest cost 
blood pressure-lowering medicines, the lowest cost statin, 
and metformin is unaffordable for 80% of households in 
low-income countries. Therefore, improving the outcomes 
of individuals with hypertension and reducing CVD 
requires a broader strategy that includes making other 
essential medicines, such as statins or glucose-lowering 
medicines, widely accessible and affordable.
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